Memory Pharmaceuticals : Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908

Sept. 26, 2008 - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced that it has completed its Phase 1 multiple ascending dose study of R4996/MEM 63908 in healthy volunteers. The multiple ascending dose study is the fourth and final study in the Company's Phase 1 program for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7 receptor being developed in collaboration with Roche. Memory Pharmaceuticals expects to report top-line results from the entire Phase 1 program in the fourth quarter of 2008.


"We conducted a robust and comprehensive Phase 1 program for R4996/MEM 63908 during which over 100 volunteers took R4996/MEM 63908. The data from these studies will provide us and our partner Roche with important insights into the safety, dosing and appropriate development path for the compound," stated Stephen Murray, M.D., Ph.D., Chief Medical Officer of Memory Pharmaceuticals. "R4996/MEM 63908, the second compound in our nicotinic alpha-7 receptor program, has the potential to address serious cognitive disorders such as Alzheimer's disease, and we look forward to analyzing the data from these studies."... Memory Pharmaceuticals' Press Release -

Memory Pharmaceuticals and Roche : R3487/MEM 3454 Development Program

Sept. 17 , 2008 - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced that it has amended its nicotinic alpha-7 receptor agonist agreement with Roche to expand the Phase 2 development program for R3487/MEM 3454 in cognitive impairment associated with schizophrenia (CIAS).

Memory Pharmaceuticals is currently conducting a Phase 2 trial of R3487/MEM 3454 in CIAS, and the companies have agreed to expand the study to allow for an increase in the target number of patients enrolled in the trial to up to approximately 212 patients, which will provide for a more robust data set and increase the potential for the study to facilitate advancing the compound into a pivotal trial. In addition, Roche has notified Memory Pharmaceuticals that it intends to initiate a Phase 2 trial of R3487/MEM 3454 in Alzheimer's disease starting either at the end of this year or at the beginning of 2009... Memory Pharmaceuticals' Press Release -

Memory Pharmaceuticals : Positive Preclinical Data for MEM 68626 at ICAD 2008

July 30, 2008 - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) presented preclinical data for MEM 68626, its lead 5-HT6 antagonist drug candidate, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago. The results demonstrate that MEM 68626 is effective in models of cognition that are considered predictive of efficacy in Alzheimer's disease and mild cognitive impairment (MCI). In addition, the data suggests the potential for once-daily oral dosing with a favorable safety and toxicology profile...
...

The results were presented in a poster titled "Characterization of serotonin 5-HT6 receptor antagonists as putative drugs for age-related mild cognitive impairment and Alzheimer's disease.".... Memory Pharmaceuticals' Press Release -

Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454 : Roche Exercises its Option to Further Develop and Commercialize it

May 2, 2008- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) and Roche (SWX: ROG) announced that Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' lead nicotinic alpha-7 agonist drug candidate, MEM 3454, for neurological and psychiatric disorders. Roche's exercise of its option for MEM 3454 triggers a $6 million milestone payment and entitles Memory Pharmaceuticals to future payments upon the achievement of additional milestones and royalties on product sales, including a $17 million milestone payment upon the completion of the ongoing Phase 2a study in cognitive impairment associated with schizophrenia (CIAS).
In addition, Memory Pharmaceuticals retains an option to co-promote MEM 3454 in the United States... Memory Pharmaceuticals' Press Release -

Memory Pharmaceuticals : Advance Development and Clinical Programs

March 12, 2008 - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced that it has realigned its operations, reallocated its resources and extended the preclinical research portion of its PDE10 collaboration with Amgen. The Company will focus its near-term and mid- term efforts on two partnered programs, its nicotinic alpha-7 receptor agonist collaboration with Roche and the PDE10 collaboration with Amgen, and two proprietary programs, its PDE4 inhibitor and 5-HT6 antagonist programs...(...)
- 5-HT6 Antagonist Program. 5-HT6 antagonists are potential treatments for Alzheimer's disease, schizophrenia, attention deficit disorder and obesity. Memory Pharmaceuticals has generated a portfolio of novel, potent and selective 5-HT6 antagonists and is evaluating several lead compounds as potential development candidates. The Company plans to advance the program into clinical trials by the end of 2008... Memory Pharmaceuticals' Press Release -

Memory Pharmaceuticals, Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease

Oct. 15 , 2007 - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal L-type calcium channel modulator, in Alzheimer's disease.The trial enrolled 183 subjects with mild to moderate Alzheimer's disease at over 40 centers in the United States and included monotherapy subjects and subjects on stable doses of cholinesterase inhibitors. The trial failed to meet its primary endpoint, which was a twelve-week mean change in the Alzheimer's disease Assessment Scale* -- Cognitive subscale (ADAS-cog) score in the overall population. ... Memory Pharmaceuticals' Press Release-